ARTICLE | Company News
CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere
September 21, 2018 9:45 PM UTC
EMA's CHMP Friday recommended several therapies for approval, including gene therapy Luxturna voretigene neparvovec, migraine mAb Emgality galcanezumab and antibiotic Vabomere meropenem/vaborbactam.
CHMP also confirmed its negative opinion for Exondys eteplirsen from Sarepta Therapeutics (NASDAQ:SRPT) for Duchenne muscular dystrophy...
BCIQ Company Profiles